Study to Evaluate HT-4253 in Healthy Subjects

NCT06537817 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

80

Enrollment

INDUSTRY

Sponsor class

Conditions

Normal Healthy Subjects

Interventions

DRUG: HT-4253
DRUG: Placebo

Sponsor

Halia Therapeutics, Inc.